The drugmaker on Feb. 5 announced it had agreed to buy three fill-finish manufacturing sites — which are in Italy, Belgium and Bloomington, Ind. — for $11 billion as part of its proposed acquisition of Catalent, a contract development and manufacturing organization based in Somerset, N.J. The deal is part of Novo’s expansion efforts to bolster supply of its popular weight loss drug Wegovy.
In October and November, FDA inspectors documented “multiple instances of workers failing to ensure the quality and purity of drugs produced,” at the Bloomington facility, according to the Bloomberg report, which is based on an FDA inspection document it obtained through a Freedom of Information Act Request. Issues flagged by inspectors include a “pest” found somewhere on a manufacturing line handling syringes last June, as well as “brown residue” in the same area.
In a statement to the news outlet, a Catalent spokesperson said the company takes “all regulatory inspections and any resulting observations very seriously,” adding the company has been given time to voluntarily fix the issue after it developed a “comprehensive response and action plans” following the November inspection.
The facility has made headlines several times in the past few years after FDA inspectors documented quality issues.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.